Inflammatory Bowel Diseases最新文献

筛选
英文 中文
Association of colonic motility on magnetic resonance enterography with endoscopic disease activity and chronic structural damage in ulcerative colitis. 溃疡性结肠炎磁共振肠造影结肠运动与内镜下疾病活动性和慢性结构损伤的关系。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-04 DOI: 10.1093/ibd/izag210
Mahshad Sarikhani, Alex Menys, Ala Torabi, Mehrnam Amouei, Homayoun Vahedi, Ali Reza Sima, Iyad Naim, Shadi Kolahdoozan, Gauraang Bhatnagar, Jean-Frédéric Colombel, Amir Reza Radmard
{"title":"Association of colonic motility on magnetic resonance enterography with endoscopic disease activity and chronic structural damage in ulcerative colitis.","authors":"Mahshad Sarikhani, Alex Menys, Ala Torabi, Mehrnam Amouei, Homayoun Vahedi, Ali Reza Sima, Iyad Naim, Shadi Kolahdoozan, Gauraang Bhatnagar, Jean-Frédéric Colombel, Amir Reza Radmard","doi":"10.1093/ibd/izag210","DOIUrl":"https://doi.org/10.1093/ibd/izag210","url":null,"abstract":"<p><strong>Background: </strong>Colonic motor dysfunction has been described in ulcerative colitis (UC) but has been less systematically assessed using quantitative imaging. We examined whether motility changes are associated with endoscopic disease activity and imaging features of disease chronicity.</p><p><strong>Methods: </strong>This prospective cross-sectional study included 49 adults with known UC who underwent magnetic resonance enterography and colonoscopy and 30 control participants. Colonic motility was quantified using GIQuant software. Endoscopic activity was graded by Mayo endoscopic subscore (MES) (0-3). Associations between motility and MES were assessed by ordinal regression and diagnostic performance by area under the curve. Imaging features of chronicity were recorded in segments with low endoscopic activity (MES ≤1).</p><p><strong>Results: </strong>GIQuant values were lower in patients with UC than control subjects in every colonic segment (mean difference -205.9 to -110.1 units; all false discovery rate-adjusted P ≤.001). Higher motility was associated with lower MES (odds ratio per 1-SD increase, 0.38; 95% confidence interval, 0.28-0.52). The area under the curve was 0.83 for MES ≥1, 0.70 for MES ≥2, and 0.73 for MES ≥3. In segments with MES ≤1, chronicity features were associated with lower GIQuant values, with the largest differences observed for loss of haustration and increased pericolic fat.</p><p><strong>Conclusions: </strong>GIQuant-derived bowel wall motion is lower in UC and inversely associated with endoscopic activity. Correlations with chronic magnetic resonance enterography features remain present in segments with MES ≤1. Prospective validation with standardized colonic cine magnetic resonance imaging and concurrent symptom measures is needed before clinical use.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pelvic radiotherapy in patients with inflammatory bowel disease: low rates of severe toxicity with modern techniques. 盆腔放射治疗炎症性肠病患者:现代技术的低严重毒性率
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-04 DOI: 10.1093/ibd/izag234
Julia Zinkin, Yonah Ziemba, Heather Zinkin, Meredith Akerman, Bhupesh Parashar
{"title":"Pelvic radiotherapy in patients with inflammatory bowel disease: low rates of severe toxicity with modern techniques.","authors":"Julia Zinkin, Yonah Ziemba, Heather Zinkin, Meredith Akerman, Bhupesh Parashar","doi":"10.1093/ibd/izag234","DOIUrl":"https://doi.org/10.1093/ibd/izag234","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visceral adiposity in pediatric Crohn disease: phenotype or disease-activity biomarker? 儿童克罗恩病的内脏脂肪:表型还是疾病活动性生物标志物?
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-02 DOI: 10.1093/ibd/izag225
Ercan Yılmaz, Nezihe Köker Özer, Erdem Topal
{"title":"Visceral adiposity in pediatric Crohn disease: phenotype or disease-activity biomarker?","authors":"Ercan Yılmaz, Nezihe Köker Özer, Erdem Topal","doi":"10.1093/ibd/izag225","DOIUrl":"https://doi.org/10.1093/ibd/izag225","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149320860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy. 接受免疫检查点抑制剂治疗的炎症性肠病患者和非炎症性肠病患者的口服免疫相关不良事件
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-02 DOI: 10.1093/ibd/izag195
Sharada Wali, Saltenat Moghaddam Adames, Sean Ngo, Tanvi Gupta, Anirudha Chatterjee, Ahmed Rehman, Mariam Rizvi, Nina Quirk, Maria Julia Nascimento Moura Santos, Carolina Colli Cruz, Stephanie Kim, Krishnavathana Varatharajalu, Michael L Dougan, Kriti Mittal, Yu Leo Lei, Mehmet Altan, Anusha Thomas, Yinghong Wang
{"title":"Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy.","authors":"Sharada Wali, Saltenat Moghaddam Adames, Sean Ngo, Tanvi Gupta, Anirudha Chatterjee, Ahmed Rehman, Mariam Rizvi, Nina Quirk, Maria Julia Nascimento Moura Santos, Carolina Colli Cruz, Stephanie Kim, Krishnavathana Varatharajalu, Michael L Dougan, Kriti Mittal, Yu Leo Lei, Mehmet Altan, Anusha Thomas, Yinghong Wang","doi":"10.1093/ibd/izag195","DOIUrl":"https://doi.org/10.1093/ibd/izag195","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) are associated with oral immune-related adverse events (irAEs). We sought to determine whether mucosal immune dysregulation in inflammatory bowel disease (IBD) predisposes patients to a higher risk or severity of these toxic effects.</p><p><strong>Methods: </strong>This retrospective cohort study evaluated adult cancer patients treated with ICIs at a tertiary cancer center between 2012 and 2024. Patients who developed oral irAEs within 1 year of starting ICIs were stratified by IBD status; IBD patients were matched 1:2 with non-IBD patients based on age, sex, and cancer type. We retrieved clinical information from electronic health records.</p><p><strong>Results: </strong>Of 450 patients treated with ICIs, 152 had pre-existing IBD. Patients with IBD had a longer median time to oral lesion onset. Oral mucosal toxic effects were significantly less frequent, and symptoms such as xerostomia, dysgeusia, mucositis, dysphagia, and oral candidiasis were all significantly lower in IBD patients. Severity grades for mucositis, oral pain, and dysphagia were similar between groups. Supportive care for oral irAEs was used less often in the IBD group. Hospitalizations due to oral lesions were rare, and ICI therapy was paused in similar proportions between groups. Recurrence of oral lesions was less frequent in IBD patients.</p><p><strong>Conclusion: </strong>Patients with IBD who receive ICIs were less likely to develop oral irAEs than those without IBD, possibly due to the protective effects of concurrent IBD therapies initiated before or during ICI treatment. These results highlight the feasibility and tolerability of ICI therapy in patients with IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149320858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Importance of higher infliximab trough level maintenance compared with the HLA-DQA1*05 polymorphism in preventing anti-infliximab antibodies and loss of response to infliximab. 与HLA-DQA1*05多态性比较,较高的英夫利昔单抗谷水平维持在预防抗英夫利昔单抗抗体和对英夫利昔单抗反应丧失中的重要性。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-01 DOI: 10.1093/ibd/izag108
Joana Revés, Ana Guedes, Ana Catarina Bravo, Maria Sá, Pedro Viana Baptista, Alexandra Ramos Fernandes, Joana Torres
{"title":"Importance of higher infliximab trough level maintenance compared with the HLA-DQA1*05 polymorphism in preventing anti-infliximab antibodies and loss of response to infliximab.","authors":"Joana Revés, Ana Guedes, Ana Catarina Bravo, Maria Sá, Pedro Viana Baptista, Alexandra Ramos Fernandes, Joana Torres","doi":"10.1093/ibd/izag108","DOIUrl":"10.1093/ibd/izag108","url":null,"abstract":"<p><p>In this single-center cohort of patients with inflammatory bowel disease (IBD) managed with proactive infliximab monitoring, HLA-DQA1*05 was not associated with immunogenicity or loss of response, whereas higher infliximab (IFX) drug levels and concomitant immunomodulator therapy independently reduced the risk of both outcomes.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2232-2236"},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry. 成年溃疡性结肠炎患者肛周疾病的临床特征和治疗要求:ENEIDA注册的PERICO研究
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-01 DOI: 10.1093/ibd/izag120
Montserrat Guasch, Margalida Calafat, Carla J Gargallo-Puyuelo, Ruth De Francisco, Irene Moraleja, Pablo Vega, Luisa de Castro, Fernando Labarga, Francisco Mesonero, Jesús Castro-Poceiro, Angel Ponferrada-Díaz, Eduard Brunet-Mas, Eva Sesé, Laura Ramos, Marta Quiñones, Alexandra Ruiz-Cerulla, Beatriz Castro, Yamile Zabana, Eva Iglesias, Irene Latras, Pilar Varela, Elena Ricart, Lucía Madero, Alfonso Elosua, Laura Vicente, Rufo Lorente, Elena Betoré, Cristina Roig, Míriam Mañosa, Eugeni Domènech
{"title":"Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.","authors":"Montserrat Guasch, Margalida Calafat, Carla J Gargallo-Puyuelo, Ruth De Francisco, Irene Moraleja, Pablo Vega, Luisa de Castro, Fernando Labarga, Francisco Mesonero, Jesús Castro-Poceiro, Angel Ponferrada-Díaz, Eduard Brunet-Mas, Eva Sesé, Laura Ramos, Marta Quiñones, Alexandra Ruiz-Cerulla, Beatriz Castro, Yamile Zabana, Eva Iglesias, Irene Latras, Pilar Varela, Elena Ricart, Lucía Madero, Alfonso Elosua, Laura Vicente, Rufo Lorente, Elena Betoré, Cristina Roig, Míriam Mañosa, Eugeni Domènech","doi":"10.1093/ibd/izag120","DOIUrl":"10.1093/ibd/izag120","url":null,"abstract":"<p><strong>Background: </strong>Perianal disease (PD) may occur in ulcerative colitis (UC), but scarce data on its features, clinical course, and common therapeutic approach are available. Our aim was to describe the prevalence, clinical characteristics and therapeutic requirements of PD among patients with UC.</p><p><strong>Methods: </strong>Patients with UC and PD were identified from the ENEIDA registry of GETECCU. Epidemiological, clinical, and therapeutic data were retrospectively gathered and reviewed from medical records.</p><p><strong>Results: </strong>From a total cohort of 9884 patients with UC, 411 developed PD, leading to an incidence rate of 0.5 cases per 100 person-years. Ninety-one patients (22%) developed PD before being diagnosed with UC. The most common perianal lesions at clinical presentation were fissures (52%), followed by fistulae (44%), and abscesses (39%). In the logistic regression analysis, male gender (OR 1.32 [95% CI, 1.10-1.58]; P = .002) and extra-intestinal manifestations (OR 1.88 [95% CI, 1.39-2.52]; P < .0001) were risk factors for PD, whereas ulcerative proctitis (OR 0.66 [95% CI, 0.51-0.86]; P = .002) was the only protective factor. Surgical techniques were used in 44% of patients with PD, and biologicals were indicated due to PD in 12%. Overall, the rate of PD remission was 91%.</p><p><strong>Conclusions: </strong>Approximately 4% of patients with UC develop PD, occurring before the diagnosis of UC in one fourth. PD seems to behave less aggressively than in Crohn's disease, being easily managed conservatively or with perianal surgery and needing biological agents only in a minority of patients.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2169-2178"},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of normalization of histology on disease course in microscopic colitis: a retrospective cohort study. 组织学标准化对显微镜下结肠炎病程的影响:一项回顾性队列研究。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-01 DOI: 10.1093/ibd/izag113
Jennifer Frances Namuli Kizza-Brown, Ashwin N Ananthakrishnan
{"title":"The impact of normalization of histology on disease course in microscopic colitis: a retrospective cohort study.","authors":"Jennifer Frances Namuli Kizza-Brown, Ashwin N Ananthakrishnan","doi":"10.1093/ibd/izag113","DOIUrl":"10.1093/ibd/izag113","url":null,"abstract":"<p><strong>Objective: </strong>Microscopic colitis (MC) is a colonic inflammatory bowel disease diagnosed via histology. There are no universally accepted guidelines defining treatment goals in MC. Our study evaluated the prognostic significance of histologic normalization in MC.</p><p><strong>Design: </strong>This retrospective cohort study identified patients with histologically confirmed MC who had at least one repeat colonoscopy with available histology. Outcomes included medical therapy use (anti-diarrheals, steroids, mesalamine, and immunosuppressants), hospitalizations, and surgeries (1) prior to or during first repeat colonoscopy or (2) after first repeat colonoscopy. Multivariable adjusted models were created for medical therapy use after first repeat colonoscopy.</p><p><strong>Results: </strong>This study included 380 MC patients. On first repeat colonoscopy, 164 (43.2%) patients normalized by histology and were more likely than those with persistent MC changes to have lymphocytic colitis (56.7% vs 43.3%, P = .036). There were no differences in hospitalization or surgery rates before or after first repeat colonoscopy for patients who normalized and those who did not. When compared to patients with MC at first repeat colonoscopy, those who normalized had statistically significant lower odds of steroids use after their first repeat colonoscopy (OR 0.26; 0.13-0.53) after multivariate adjustment. This association remained significant when restricted to patients with symptoms at first repeat colonoscopy (OR 0.22; 0.08-0.59) but was weaker for patients without symptoms (OR 0.45; 0.16-1.29).</p><p><strong>Conclusion: </strong>In patients with MC, histologic normalization at first repeat colonoscopy was associated with reduced need for corticosteroids on follow-up. The effect was slightly attenuated in asymptomatic patients. Future studies of histologic normalization as a treatment target in MC are warranted.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2142-2151"},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13722121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148198877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wearable perspiration sensor for continuous inflammation tracking in inflammatory bowel disease. 用于炎症性肠病持续炎症跟踪的可穿戴式汗液传感器。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-01 DOI: 10.1093/ibd/izag173
Sarah Shahub, Kai-Chun Lin, Natalie K Choi, Nicole M Garcia, Sriram Muthukumar, David T Rubin, Shalini Prasad
{"title":"Wearable perspiration sensor for continuous inflammation tracking in inflammatory bowel disease.","authors":"Sarah Shahub, Kai-Chun Lin, Natalie K Choi, Nicole M Garcia, Sriram Muthukumar, David T Rubin, Shalini Prasad","doi":"10.1093/ibd/izag173","DOIUrl":"10.1093/ibd/izag173","url":null,"abstract":"<p><strong>Background: </strong>Wearable sensors present an opportunity to monitor inflammation via noninvasive media such as perspiration, which may be sampled continuously to track biomarkers in inflammatory bowel disease (IBD). Here we demonstrate the use of a perspiration sensor for C-reactive protein (CRP) and calprotectin and their clinical significance.</p><p><strong>Methods: </strong>Thirty-three patients with IBD were enrolled in a cross-sectional study of CRP and calprotectin perspiration expression compared to expression in serum and stool, respectively. Perspiration on-body measurements were obtained every minute using a wearable sensor worn for 40-130 minutes during standard of care assessment. Synchronously collected serum levels were measured, as was fecal calprotectin from a subcohort.</p><p><strong>Results: </strong>Principal component analysis of demographic data identified age, disease activity, and diagnosis as the major contributors to variance in the dataset. When endoscopic scores were incorporated into the PCA, both disease activity and endoscopy score were identified as contributing most strongly to the primary variance. In perspiration and serum, median CRP was observed to be elevated in patients with Crohn's disease (CD) compared to ulcerative colitis, while median calprotectin was elevated in UC compared to CD. Median calprotectin across perspiration, serum, and stool was observed to be elevated in IBD of the colon over isolated ileal IBD. Furthermore, median perspiration and serum CRP were elevated in patients under 40 years of age compared to those 40 and older, whereas median perspiration, serum, and fecal calprotectin were elevated in patients 40 and older compared to the younger cohort.</p><p><strong>Conclusions: </strong>We report the use of a noninvasive perspiration sensor for tracking inflammatory markers in patients with IBD and demonstrate consistency of perspiration CRP and calprotectin measurements with corresponding serum and stool measurements.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2095-2102"},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of isolated periappendiceal red patch in ulcerative colitis: A systematic review, meta-analysis, and meta-regression. 孤立性阑尾周围红斑在溃疡性结肠炎中的临床意义:一项系统综述、荟萃分析和荟萃回归。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-01 DOI: 10.1093/ibd/izag092
Khawaja Abdul Rehman, Noor Us Sehar, Umar Akram, Eeshal Fatima, Sahar Ahsan, Syed Zaeem Ahmed, Ahmed Faizan, Saman Javid, Syed Adeel Hassan, Jeffrey Aaron Berinstein, Terrence A Barrett
{"title":"Clinical significance of isolated periappendiceal red patch in ulcerative colitis: A systematic review, meta-analysis, and meta-regression.","authors":"Khawaja Abdul Rehman, Noor Us Sehar, Umar Akram, Eeshal Fatima, Sahar Ahsan, Syed Zaeem Ahmed, Ahmed Faizan, Saman Javid, Syed Adeel Hassan, Jeffrey Aaron Berinstein, Terrence A Barrett","doi":"10.1093/ibd/izag092","DOIUrl":"10.1093/ibd/izag092","url":null,"abstract":"<p><strong>Objectives: </strong>Ulcerative colitis (UC) is characterized by continuous mucosal inflammation beginning in the rectum with variable proximal extension. However, up to 17% of patients demonstrate patchy cecal inflammation known as a periappendiceal red patch (PARP). Although PARP has historically been linked to severe disease and worse outcomes, its long-term clinical significance remains unclear. We conducted a systematic review and meta-analysis to evaluate outcomes in UC patients with isolated PARP.</p><p><strong>Methods: </strong>A comprehensive literature search of MEDLINE, Embase, Scopus, and Cochrane CENTRAL was performed to identify studies comparing UC patients with and without endoscopic or histologic evidence of PARP. Meta-analysis was conducted using R (version 4.4.3). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, and between-study heterogeneity was assessed using Higgins' I2 statistic.</p><p><strong>Results: </strong>Thirteen nonrandomized studies, including 2289 UC patients (PARP+: 725; PARP-: 1564), were analyzed. PARP was significantly associated with higher odds of proctitis (OR, 1.54; 95% CI, 1.09-2.18; P = .02). No significant associations were observed between PARP and left-sided colitis (OR, 0.88; 95% CI, 0.57-1.35; P = .51) or extensive colitis (OR, 0.84; 95% CI, 0.50-1.41; P = .45). PARP was not associated with disease progression, pharmacotherapeutic escalation, or colectomy. However, moderate-to-high heterogeneity was observed across most of the outcomes.</p><p><strong>Conclusion: </strong>PARP is more frequently observed in patients with ulcerative proctitis but does not appear to influence long-term disease progression or major clinical outcomes, supporting its classification as a benign endoscopic finding in UC.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2179-2192"},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of preoperative neoplasia and rectal cuff inflammation on initial pouchoscopy with subsequent neoplasia development in inflammatory bowel disease patients with an ileal pouch-anal anastomosis: a case-control study. 一项病例对照研究:炎性肠病患者回肠袋-肛门吻合术术前瘤变和直肠袖口炎症与随后瘤变发展的关系
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-01 DOI: 10.1093/ibd/izag112
Joseph Carter Powers, Mark Zemanek, Mili Dave, Emma Dester, Katherine Westbrook Cates, Riley Smith, Tracy Hull, Olga Lavryk, Benjamin L Cohen, Bret Lashner, Andrei I Ivanov, Edward Barnes, Katherine Falloon, Manuel Braga-Neto, Taha Qazi
{"title":"Association of preoperative neoplasia and rectal cuff inflammation on initial pouchoscopy with subsequent neoplasia development in inflammatory bowel disease patients with an ileal pouch-anal anastomosis: a case-control study.","authors":"Joseph Carter Powers, Mark Zemanek, Mili Dave, Emma Dester, Katherine Westbrook Cates, Riley Smith, Tracy Hull, Olga Lavryk, Benjamin L Cohen, Bret Lashner, Andrei I Ivanov, Edward Barnes, Katherine Falloon, Manuel Braga-Neto, Taha Qazi","doi":"10.1093/ibd/izag112","DOIUrl":"10.1093/ibd/izag112","url":null,"abstract":"<p><strong>Background and aims: </strong>Neoplasia of the pouch or rectal cuff is a rare cause of pouch failure in patients with an ileal pouch-anal anastomosis. Cuff inflammation has been suggested to convey a higher neoplasia risk but has not been thoroughly investigated. This study evaluated whether endoscopic inflammation of the rectal cuff conveys increased risk of subsequent neoplasia development.</p><p><strong>Methods: </strong>This was a 2-institution case-control study of inflammatory bowel disease patients who developed neoplasia of the rectal cuff or ileal pouch and patients without neoplasia. Cases were matched to controls in a 1:4 ratio. Neoplasia was defined as dysplasia or adenocarcinoma, and cuff inflammation was defined as endoscopic evidence of erythema, edema, and/or ulcerations. A subanalysis assessed whether persistent inflammation conveys a higher neoplasia risk than resolved cuff inflammation.</p><p><strong>Results: </strong>Forty-six cases of neoplasia were matched to 184 controls. Rectal cuff dysplasia (n = 23) was most common, followed by pouch dysplasia, cuff cancer, pouch cancer, and neoplasia involving both sites. Patients with cuff inflammation on initial pouchoscopy (adjusted odds ratio [aOR] = 2.82; 95% CI, 1.24-7.74; P = .013) had a higher risk of developing neoplasia. Compared to controls, patients with persistent cuff inflammation had a higher risk of neoplasia development (aOR = 3.70; 95% CI, 1.37-9.97; P = .010), but this trend was not observed in patients with inflammation on only one pouchoscopy.</p><p><strong>Conclusions: </strong>Patients with inflammation of the rectal cuff on initial pouchoscopy are at higher risk of subsequent neoplasia development, and this risk appears highest in patients with persistent inflammation.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2152-2160"},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148360695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书